Log-rank testing showed that GBM patients with high IL1B expression showed significantly shorter overall survival (Figure 3C, p = 0.034), similar to patients expressing high CEBPB (Figure 2C, p = 0.0497). This evidence concerns the gene CEBPB and glioblastoma.